Why TAVI vs SAVR is not just age
Age matters in the TAVI vs SAVR decision — but it is a proxy, not the decision itself. Understanding what age is standing in for helps make better sense of the Heart Team's reasoning.
When the AS Intervention Navigator flags TAVI as the likely approach in an 80-year-old, it is not because of age alone. Age is a proxy for several things that actually drive the decision.
Key takeaway
Age matters because it correlates with life expectancy, frailty, and surgical risk — but none of these are synonymous with age. The Heart Team weighs anatomy, access, and strategy, not just a birthdate.
Key points
- Age is a meaningful input, but it is a proxy for life expectancy, frailty, and physiologic reserve.
- Transfemoral access feasibility is a prerequisite for standard TAVI advantage — without it, the calculus changes.
- Frailty is an independent predictor of outcomes, separate from age and surgical risk scores.
- SAVR remains highly effective — in the right patient, it is not the 'harder' option, it is the correct one.
- The Heart Team exists because the answer is rarely one-click.
When to read this
You have a result from the AS Intervention Navigator and are wondering why TAVI, SAVR, or a Heart Team discussion was flagged — or why age is factoring in but not deciding things alone.
Age matters — but here is what it is standing in for
In major randomized trials, TAVI and SAVR showed equivalent short-term outcomes in low- and intermediate-risk patients, and TAVI was superior in high-risk and extreme-risk patients. Age was a consistent predictor of outcomes across these trials — but largely because older patients had shorter life expectancy, more frailty, and less physiologic reserve to survive open surgery and recover from it. Age at 65 and age at 82 mean very different things clinically.
Life expectancy and valve durability
TAVI valve durability beyond 10 years remains uncertain in most populations. This matters less for a patient who is 83 with limited life expectancy, and matters a great deal for someone who is 62. Placing a TAVI valve in a patient likely to outlive its durability creates downstream problems: future valve-in-valve procedures require specific anatomical conditions, and not all patients are candidates. SAVR with a bioprosthetic or mechanical valve remains the more durable option for patients with decades ahead.
Transfemoral access changes the calculation
The major TAVI advantage in high-risk patients was demonstrated with transfemoral access. Alternative access routes — transapical, transaortic, transcaval — carry higher complication rates and may eliminate the procedural risk advantage that makes TAVI appealing in the first place. Before treating TAVI as the default for older patients, confirming transfemoral feasibility is essential.
Frailty is not the same as age
Frailty — assessed formally by tools like the Clinical Frailty Scale or informally by gait speed, grip strength, and functional status — is a stronger predictor of post-procedural outcomes than STS score in many populations. A frail 75-year-old may have worse outcomes than a robust 80-year-old. TAVI's lower procedural burden is particularly advantageous in frail patients, regardless of exact age.
The Heart Team exists for a reason
ACC/AHA VHD 2020 recommends Heart Team evaluation for most AVR decisions. This is not bureaucratic caution — it reflects the genuine complexity of integrating anatomy, physiology, patient preferences, institutional experience, and lifetime strategy into a single recommendation. When a tool flags 'Heart Team,' that is not a failure to decide — it is the appropriate clinical process.
Common mistake
Framing TAVI as 'the easy option for old patients' and SAVR as 'the right option for young patients.' Both procedures have indications, risks, and trade-offs. The question is which fits this patient's anatomy, physiology, preferences, and expected trajectory.
Apply this in practice
Evaluate AVR indication and approach in the AS Intervention Navigator.
Return to AS Intervention Navigator